Health Dept welcomes arrival of new HIV prevention medicine Lenacapavir
This image was generated by AI and may not depict real events.
South Africa has received its first batch of Lenacapavir, a new HIV prevention medicine. The medication is a six-monthly injectable that is expected to strengthen the country's HIV prevention efforts and help reduce new infections.
The Department of Health has welcomed the arrival of South Africa's first batch of Lenacapavir, a new HIV prevention medicine. Close to 38,000 doses have landed in the country. Lenacapavir is a long-acting capsid inhibitor for multidrug-resistant HIV. It is taken twice a year and is designed to improve adherence, especially among vulnerable groups. The department will announce the official launch and phased implementation plan in the next few weeks. Lenacapavir is expected to help reduce new infections and support South Africa's goal of ending AIDS as a public health threat by 2030.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.